Examining Biomarker Testing in Early-stage NSCLC

Biomarker testing has become increasingly important in the management of early-stage non–small cell lung cancer (NSCLC), guiding both targeted therapy selection and prognostic assessment. Early identification of actionable mutations, such as EGFR, ALK, and PD-L1 expression, allows for more personalized treatment planning and may inform decisions regarding adjuvant or neoadjuvant therapy. Despite clear benefits, comprehensive biomarker testing remains underutilized in early-stage disease due to logistical challenges, tissue availability, and variability in clinical practice. Increasing awareness of guideline recommendations, integrating molecular testing into standard diagnostic workflows, and leveraging multidisciplinary collaboration can enhance uptake. By systematically incorporating biomarker testing, clinicians can optimize treatment selection, identify patients eligible for emerging targeted therapies, and improve long-term outcomes, ultimately shifting the management of early-stage NSCLC toward a more precision-based, patient-centered approach.